Two independent studies demonstrate that IGFBP-2 correlates with worsened survival in pancreatic ductal adenocarcinoma (PDAC) and that IGFBP-2 stimulates STAT3 signaling, leading to immune suppression phenotypes. The gene discussed is IGFBP2; the disease is pancreatic ductal adenocarcinoma.